156 related articles for article (PubMed ID: 26504891)
1. Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
Data Brief; 2015 Dec; 5():107-13. PubMed ID: 26504891
[TBL] [Abstract][Full Text] [Related]
2. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
3. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
4. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
5. Structure and ligand interactions of the urokinase receptor (uPAR).
Kjaergaard M; Hansen LV; Jacobsen B; Gardsvoll H; Ploug M
Front Biosci; 2008 May; 13():5441-61. PubMed ID: 18508598
[TBL] [Abstract][Full Text] [Related]
6. Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion.
Kanse SM; Chavakis T; Kuo A; Bdeir K; Cines DB; Preissner KT
Cell Biochem Funct; 2004; 22(4):257-64. PubMed ID: 15248186
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
8. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
9. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
10. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
11. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
12. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
13. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
[TBL] [Abstract][Full Text] [Related]
14. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
15. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
16. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.
Kriegbaum MC; Persson M; Haldager L; Alpízar-Alpízar W; Jacobsen B; Gårdsvoll H; Kjær A; Ploug M
Curr Drug Targets; 2011 Nov; 12(12):1711-28. PubMed ID: 21707479
[TBL] [Abstract][Full Text] [Related]
17. Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?
Leth JM; Mertens HDT; Leth-Espensen KZ; Jørgensen TJD; Ploug M
J Biol Chem; 2019 May; 294(18):7403-7418. PubMed ID: 30894413
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.
Leth JM; Ploug M
Front Cell Dev Biol; 2021; 9():732015. PubMed ID: 34490277
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
20. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
Li Y; Parry G; Chen L; Callahan JA; Shaw DE; Meehan EJ; Mazar AP; Huang M
J Mol Biol; 2007 Jan; 365(4):1117-29. PubMed ID: 17101149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
